Laboratory Co. of America Holdings (NYSE:LH) Shares Sold by Leeward Investments LLC MA

Leeward Investments LLC MA reduced its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 3.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 56,640 shares of the medical research company’s stock after selling 1,951 shares during the quarter. Leeward Investments LLC MA’s holdings in Laboratory Co. of America were worth $12,989,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Private Trust Co. NA grew its position in Laboratory Co. of America by 3.2% during the 3rd quarter. Private Trust Co. NA now owns 1,342 shares of the medical research company’s stock worth $300,000 after purchasing an additional 41 shares during the last quarter. Empowered Funds LLC grew its position in Laboratory Co. of America by 0.5% during the 4th quarter. Empowered Funds LLC now owns 8,025 shares of the medical research company’s stock worth $1,840,000 after purchasing an additional 43 shares during the last quarter. Empirical Finance LLC grew its position in Laboratory Co. of America by 1.7% during the 3rd quarter. Empirical Finance LLC now owns 3,055 shares of the medical research company’s stock worth $683,000 after purchasing an additional 50 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Laboratory Co. of America by 16.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 354 shares of the medical research company’s stock worth $81,000 after purchasing an additional 50 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its position in Laboratory Co. of America by 28.2% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 232 shares of the medical research company’s stock worth $53,000 after purchasing an additional 51 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Laboratory Co. of America Stock Up 0.3 %

Shares of NYSE LH opened at $249.86 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $258.59. The firm has a 50-day moving average price of $238.93 and a 200 day moving average price of $231.74. The stock has a market capitalization of $20.90 billion, a price-to-earnings ratio of 28.33, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. Equities research analysts anticipate that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.15%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is 32.65%.

Wall Street Analysts Forecast Growth

LH has been the topic of several research reports. Piper Sandler raised their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. UBS Group lowered their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Bank of America raised their price objective on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Jefferies Financial Group lifted their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Finally, Barclays lowered their target price on shares of Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a report on Friday, February 7th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Laboratory Co. of America currently has a consensus rating of “Moderate Buy” and a consensus price target of $265.31.

Insider Activity at Laboratory Co. of America

In other Laboratory Co. of America news, Director Dwight Gary Gilliland sold 1,000 shares of Laboratory Co. of America stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $241.00, for a total transaction of $241,000.00. Following the completion of the transaction, the director now owns 7,712 shares in the company, valued at approximately $1,858,592. The trade was a 11.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Glenn A. Eisenberg sold 11,711 shares of Laboratory Co. of America stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $240.43, for a total transaction of $2,815,675.73. Following the transaction, the executive vice president now owns 31,289 shares of the company’s stock, valued at approximately $7,522,814.27. The trade was a 27.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 19,832 shares of company stock worth $4,788,995 over the last 90 days. Company insiders own 0.85% of the company’s stock.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.